SCHMID Group (SHMD) Q2 2026 earnings review
Explosive Order Growth Overshadowed by Margin Cut and Severe Dilution Overhang
SCHMID's H1 2026 paints a tale of two extremes. Top-line performance is accelerating rapidly, with revenue up 172% YoY to €46.0M and a massive surge in Q3 order intake. However, this growth came at a steep cost. Margins disappointed due to a heavier mix of lower-margin Chinese business, forcing management to slash full-year Adjusted EBITDA guidance from >12% to 6-9%. Meanwhile, the bottom line was decimated by €38.8M in financial costs tied to liability conversions, pushing net losses to €47.8M. While the restructuring phase appears to be yielding commercial momentum, the path to sustained profitability is heavily burdened by working capital cash burn and a complex, highly dilutive capital structure.
🐂 Bull Case
Order momentum is violently accelerating. Q1 intake of €13.6M grew to €30.7M in Q2, and exploded to €52.3M in just the first half of Q3 (through Aug 21). The company expects to hit the upper half of its €125-150M annual order guidance.
Management successfully converted €30.75M of debt owed to the Schmid family into equity, cleaning up the balance sheet and reducing immediate cash obligations to allow for growth investments.
🐻 Bear Case
Gross margin landed at just 21.2%. The heavy reliance on the Chinese market—which performs well on volume but poorly on price—forced a dramatic cut to the FY26 Adjusted EBITDA margin target, dropping the floor from >12% to just 6%.
The complex web of convertible notes, warrants, and options presents an extreme dilution overhang. At a $12 share price, an additional 14.9 million shares could be issued, diluting the existing ~61 million base by 20%.
⚖️ Verdict: 🔴
Bearish. The violent acceleration in order intake proves demand for SCHMID's technology is real. However, the combination of a severe margin guidance cut, massive cash absorption into working capital, and an opaque, highly dilutive financial structure makes the equity uninvestable until margins stabilize.
Key Themes
Violent Acceleration in Order Intake
The strongest data point in the release is the forward-looking order book. Order intake is accelerating sequentially at an exceptional pace. Total backlog has nearly doubled from €54.8M on June 30 to €95.0M by late August. If this conversion rate holds, 2027 revenue visibility is highly secure.
Technical Equipment Hardware Demand Resurging
Revenue growth was entirely driven by the Technical Equipment & Processes segment, which surged 268% YoY from €10.7M to €39.4M. This was supported by major deployments, including the delivery of the first specialized InfinityLine H+ system for panel-level packaging to a leading U.S. technology company.
Restructuring and Deleveraging Complete
The company reduced financial debt by nearly €30M in H1, largely via debt-to-equity conversions. This deleveraging is critical for survival and shifts the narrative from liquidity preservation to operational execution.
Geographic Mix Crushes Margins
Macro resilience in China actually hurt the bottom line. Because Chinese demand outperformed expectations while the higher-margin German manufacturing plant lagged, the resulting product mix compressed gross margins to 21.2%. The company expects roughly equal revenue splits between the two plants in H2, which is required to rescue profitability.
Operating Cash Burn Contradicts Deleveraging Narrative
While management highlighted debt reduction, operational cash flow was disastrously negative at €-29.3M. This was driven by a €26.1M cash drain to rebuild working capital. Re-establishing normal working capital levels was necessary, but it consumed the vast majority of cash raised through financing activities.
Extreme Dilution Threat Looms
The capital structure is a minefield for equity holders. The 2028 and 2029 Convertible Notes, multiple tranches of warrants, and the 2025 Convertible Loan pose systemic dilution risks. Management's own illustrative table shows that if the stock price rises to $12.00, it triggers the issuance of 14.9 million new shares—a 20% dilution event.
Cost Cutting Transitions from 'Sprint' to 'Sprint II'
To combat margin compression, SCHMID reduced German overhead by 40 FTEs (expecting €4M in annual savings). They are now launching 'Sprint II', targeting a 5% reduction in material expenses. Execution here is vital since pricing power appears limited in the current geographic mix.
Other KPIs
Improved from €-11.6 million a year ago. However, this metric excludes €1.4M in share-based compensation, €0.4M in restructuring costs, and €1.4M in advisory fees for capital structure changes. Real cash profitability remains a challenge.
A massive drag on net income, up from €-2.3M last year. This was primarily driven by non-cash effects related to the accounting treatment of the XJ Harbour liability conversion and fair-value movements of company warrants.
Guidance
Stable. The company confirmed its prior guidance. With €46M achieved in H1 and an exploding order backlog, this target appears highly secure and implies H2 revenue will slightly outpace H1.
Decelerating. This is a severe downgrade from the previously communicated guidance of 'more than 12%'. Management attributes the cut to the weaker-than-expected margin profile in H1, forcing reliance on H2 overhead cuts and a better product mix to hit even this lowered bar.
Accelerating. Guidance range was maintained, but management explicitly noted they expect to land in the 'upper half' of the range. Sitting at €96.6M by late August implies they only need ~€40M across the remaining 4 months to hit the top end.
Key Questions
German Plant Acceleration
You are relying heavily on the German plant accelerating in H2 to offset the lower-margin Chinese mix. What specific leading indicators or customer sign-offs give you confidence this pivot will occur in Q3/Q4?
Working Capital Burn
Working capital consumed €26.1M in H1. As order intake scales rapidly toward the €150M mark, what is the expected ongoing cash drain required to fund inventory and receivables for this growth?
Zhongshan Campus Financing
The new €11 million manufacturing campus in Guangdong is to be financed via local project financing. Have these terms been fully secured, and are there any covenants that could restrict cash repatriation to the parent entity?